Cytokeratin 15 Antibody (0.N.360): sc-70912

Cytokeratin 15 Antibody (0.N.360) is a mouse monoclonal IgG2a antibody that detects Cytokeratin 15 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry with paraffin-embedded sections (IHCP). Cytokeratin 15 is an essential intermediate filament protein that plays a critical role in maintaining the mechanical integrity of epithelial cells, particularly in the hair follicle bulge where Cytokeratin 15 serves as a specific marker for stem cells. Cytokeratin 15 localization contributes to the structural framework of epithelial tissues, ensuring resilience against mechanical stress and injury. Cytokeratin 15 (0.N.360) antibody helps distinguish between basal cell carcinoma and trichoepithelioma, as both conditions exhibit overlapping morphological features that can complicate diagnosis. Anti-Cytokeratin 15 antibody (0.N.360) enables researchers to effectively identify and characterize these conditions, enhancing diagnostic accuracy and contributing to better patient management. Cytokeratin 15 monoclonal antibody (0.N.360) recognition across various species underscores utility in diverse research and clinical applications, making anti-Cytokeratin 15 antibody (0.N.360) an invaluable tool for studies related to epithelial biology and cancer pathology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cytokeratin 15 Antibody (0.N.360) References:

1. Cytokeratin 15 expression in trichoepitheliomas and a subset of basal cell carcinomas suggests they originate from hair follicle stem cells.  |  Jih, DM., et al. 1999. J Cutan Pathol. 26: 113-8. PMID: 10235375
2. Cytokeratin 15 expression in apocrine mixed tumors of the skin and other benign neoplasms with apocrine differentiation.  |  Misago, N. and Narisawa, Y. 2006. J Dermatol. 33: 2-9. PMID: 16469077
3. Cytokeratin 15 can be used to identify the limbal phenotype in normal and diseased ocular surfaces.  |  Yoshida, S., et al. 2006. Invest Ophthalmol Vis Sci. 47: 4780-6. PMID: 17065488
4. Elastic fiber staining and cytokeratin 15 expression pattern in trichoepithelioma and basal cell carcinoma.  |  Choi, CW., et al. 2008. J Dermatol. 35: 499-502. PMID: 18789069
5. Expression of stem cell markers nestin and cytokeratin 15 and 19 in cutaneous malignancies.  |  Abbas, O. and Bhawan, J. 2011. J Eur Acad Dermatol Venereol. 25: 311-6. PMID: 20629844
6. Cytokeratin 15 expression in central, centrifugal, cicatricial alopecia: new observations in normal and diseased hair follicles.  |  Sperling, LC., et al. 2011. J Cutan Pathol. 38: 407-14. PMID: 21251039
7. Cytokeratin 15 marks basal epithelia in developing ureters and is upregulated in a subset of urothelial cell carcinomas.  |  Tai, G., et al. 2013. PLoS One. 8: e81167. PMID: 24260555
8. HOXA10 Regulates Expression of Cytokeratin 15 in Endometrial Epithelial Cytoskeletal Remodeling.  |  Kallen, AN., et al. 2014. Reprod Sci. 21: 892-897. PMID: 24532216
9. Comparative analysis of cytokeratin 15, TDAG51, cytokeratin 20 and androgen receptor in sclerosing adnexal neoplasms and variants of basal cell carcinoma.  |  Evangelista, MT. and North, JP. 2015. J Cutan Pathol. 42: 824-31. PMID: 26016446
10. Cytokeratin 15 is a novel and independent predictor of poor outcome in luminal B HER2-negative breast carcinomas.  |  Lee, DHY., et al. 2024. Pathology. 56: 834-841. PMID: 38909003

The preferred Cytokeratin 15 antibody is Cytokeratin 15 Antibody (LHK15): sc-47697.